LAMP1

Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023

Retrieved on: 
Tuesday, October 31, 2023
EGFR, Society for Immunotherapy of Cancer, Neoplasm, CAR, Ovarian cancer, Assistant, CD20, HER2, University, Research, CD69, Mouse, SNAP, SITC, Immunotherapy, Poster, Division, San Diego Convention Center, Cancer, University of Pittsburgh, LAMP1, Leukemia, NSG, Epitope, Society, Therapy, Immunology, Toxic shock syndrome toxin-1, Mobile phone, Vaccine

WEXFORD, Pa., Oct. 31, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that research demonstrating the potential of the SNAP-CAR T-cell platform to target multiple antigens, including HER2 and CD20, through combinatorial use of different adaptors will be the subject of a poster presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023). SITC 2023 is being held Nov. 1–5, 2023, at San Diego Convention Center in San Diego. 

Key Points: 
  • SITC 2023 is being held Nov. 1–5, 2023, at San Diego Convention Center in San Diego.
  • Further, in another leukemia model targeting the CD20 antigen, SNAP-CAR T cells showed significant inhibition of tumor growth.
  • "While still early in its development, we continue to see vast potential for the SNAP-CAR platform for treating both liquid and solid tumor malignancies."
  • "The data being presented at SITC 2023 encapsulates the groundbreaking research being conducted at the University of Pittsburgh, which demonstrates the potential of SNAP-CAR T-cells to reduce tumor burden and tumor growth in numerous cancers, including HER2-expressing and CD20-expressing cancers," said Dave Mehalick, President and CEO of Coeptis Therapeutics.

OncoOne Presents Preclinical Data Update from oxMIF-targeting Pipeline at the 2023 AACR Annual Meeting

Retrieved on: 
Friday, April 14, 2023
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Pancreatic cancer, Radiation, AACR, Molecule, CRC, Doctor of Philosophy, Granzyme, CD16, Macrophage, Cancer, Coronavirus Scientific Advisory Board, Granzyme B, Tumor microenvironment, NK, Assistant, LAMP1, Harvard Medical School, HSG, American Association for Cancer Research, Patient, Colorectal cancer, Annual general meeting, TME, Neoplasm, Poster, Natural killer T cell, Vaccine, Pharmaceutical industry

Alexander Schinagl, Ph.D., CTO of OncoOne added: “We are pleased to see that our PreTarg-it® program, ON-05, demonstrated such promising initial preclinical results including significant tumor regression.

Key Points: 
  • Alexander Schinagl, Ph.D., CTO of OncoOne added: “We are pleased to see that our PreTarg-it® program, ON-05, demonstrated such promising initial preclinical results including significant tumor regression.
  • The data build on and strengthen the excellent tumor penetration, tumor retention and reduced tumor proliferation preclinical data shown in previously analyzed mouse models.
  • These preclinical data highlight the potential of ON203 to significantly modulate the TME towards immune-stimulating functions in tumor material collected from patients.
  • Both posters will be available on OncoOne’s website upon conclusion of the AACR 2023 Annual Meeting.

Gamida Cell Reports Full Year 2022 Financial Results and Provides Company Update

Retrieved on: 
Monday, March 27, 2023
Research, Clinical Trials, Health Technology, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, Oncology, Haematopoiesis, Ministry of Health (Israel), EAP, University, ASH, Therapy, Integrin alpha-1, CD16, T&E, CD57, Neoplasm, Survival, NK, Toxicity, Tandem, Cell, IP, Rated R, LAMP1, TCT, Ministry, Incidence, Highbridge Capital Management, Center for International Blood and Marrow Transplant Research, LAG3, Patient, CD56, University of Minnesota Medical School, CD62L, PDUFA, Viral, Poster, FDA, Society, Safety, Cryptocurrency, Pharmaceutical industry, Dentistry, Vaccine, Security (finance), Transplant

Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the year ended December 31, 2022.

Key Points: 
  • Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the year ended December 31, 2022.
  • As of December 31, 2022, Gamida Cell had total cash and cash equivalents of $64.7 million.
  • “Our mission is to bring potentially curative therapies to patients,” said Abbey Jenkins, President and Chief Executive Officer of Gamida Cell.
  • Especially since our engineered NK cell therapy candidates, which are derived from healthy donors, have demonstrated encouraging pre-clinical data that differentiate them from other NK cell therapy approaches.

Data Presented on Gamida Cell’s Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR

Retrieved on: 
Saturday, February 18, 2023
Research, Genetics, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Toxicity, Therapy, Hope, University of Minnesota Medical School, CD62L, CD56, TCT, Safety, Phenotype, NK, Patient, Tandem, CD16, LAG3, Cell, Center for International Blood and Marrow Transplant Research, University, Lymph, Bone marrow, Integrin alpha-1, Knowledge, Society, Transplant, CD57, LAMP1, Spatial analysis, Non-Hodgkin lymphoma, Pharmaceutical industry, Medical imaging

The meetings took place February 15-19 virtually and in person in Orlando, Florida.

Key Points: 
  • The meetings took place February 15-19 virtually and in person in Orlando, Florida.
  • “The data presented at Tandem demonstrate Gamida Cell’s expertise in developing potent, potentially curative cell therapies for patients with hematologic malignancies,” said Ronit Simantov, M.D., chief medical and scientific officer of Gamida Cell.
  • “The translational data from our Phase 3 study of omidubicel, our lead product candidate, show faster, multi-faceted immune response – as quickly as seven days—in omidubicel-treated patients compared to standard cord blood.
  • Patients transplanted with standard cord blood showed no such correlations at Day 7 post-transplant, and only began to show correlations starting at 14 days post-transplant.

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

Retrieved on: 
Monday, December 12, 2022
Canadian Aviation Regulations, Annual report, University, LAMP1, Society, NK, Trike, Diagnosis, Disorder, CAR, GT, Security (finance), Neoplasm, Health, Cancer, CD38, ASH, American Society of Hematology, University of Minnesota College of Biological Sciences, Education, IPSC, AML, Consultant, MD, GTBP, Form 10-K, Acute myeloid leukemia, Destiny, Kinetics, Research, Therapy, Risk, Patient, Vaccine, Blood, Hematology

BRISBANE, CALIFORNIA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) today announced the presentation of new preclinical data at the American Society of Hematology's 64th Annual Meeting (ASH 2022). The presentation highlights the potential of a novel dual antigen targeting approach for the treatment of acute myeloid leukemia (AML) by combining GT Biopharma’s Tri-specific Killer Engager (TriKE) with the induced pluripotent stem cell (iPSC) product platform of Fate Therapeutics, Inc. (NASDAQ:FATE).

Key Points: 
  • BRISBANE, CALIFORNIA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) today announced the presentation of new preclinical data at the American Society of Hematology's 64th Annual Meeting (ASH 2022).
  • The presentation highlights the potential of a novel dual antigen targeting approach for the treatment of acute myeloid leukemia (AML) by combining GT Biopharma’s Tri-specific Killer Engager (TriKE) with the induced pluripotent stem cell (iPSC) product platform of Fate Therapeutics, Inc. (NASDAQ:FATE).
  • Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer.
  • GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology.

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium

Retrieved on: 
Wednesday, October 26, 2022
Myelodysplastic syndrome, LAMP1, Warsaw Stock Exchange, Hematology, Șaeș, Lymphatic system, DLBCL, MTA, Merck, Rituximab, ADCC, Acute myeloid leukemia, Neoplasm, Patient, EORTC, Culture, PRMT5, Symposium, GLOBE, NK, AES, DLT, Therapy, WSE, Knowledge, MTAP, CD20, Galápagos Islands, Mouse, Pharmaceutical industry, Vaccine

RVU120 monotherapy continues to be safe, well-tolerated and the dose escalation has now progressed to a dose of 175mg.

Key Points: 
  • RVU120 monotherapy continues to be safe, well-tolerated and the dose escalation has now progressed to a dose of 175mg.
  • Additionally, we presented data from our preclinical studies showing that RVU120 enhances the therapeutic potential of ADCC-promoting drugs in-vivo and in-vitro.
  • Dr. Nogai continued, We also presented preclinical data with our proprietary MTA-cooperative PRMT5 inhibitors that selectively target MTAP deficiency which occurs in 10-15% of all tumors.
  • Ryvu Therapeutics has signed multiple partnering and licensing deals with global companies, including Merck, Menarini Group, Galapagos and Exelixis.

Ryvu Therapeutics Announces Poster Presentations at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium

Retrieved on: 
Wednesday, October 12, 2022
Merck, Therapy, Culture, PD, Growth, Acute myeloid leukemia, DLT, Warsaw Stock Exchange, PRMT5, Animal, Rituximab, Patient, Cell, Collection, Myelodysplastic syndrome, Knowledge, MTA, LAMP1, AACR, DLBCL, IP, MTAP, GLOBE, Galápagos Islands, ADCC, NK, Lymphatic system, Cancer, IC50, SAE, Hematology, WSE, Adenoid cystic carcinoma, Pharmaceutical industry, Vaccine

We are excited to present updated clinical and preclinical data on RVU120 and our novel MTA-cooperative PRMT5 inhibitors at this years AACR-NCI-EORTC symposium," said Hendrik Nogai, M.D., Chief Medical Officer of Ryvu Therapeutics.

Key Points: 
  • We are excited to present updated clinical and preclinical data on RVU120 and our novel MTA-cooperative PRMT5 inhibitors at this years AACR-NCI-EORTC symposium," said Hendrik Nogai, M.D., Chief Medical Officer of Ryvu Therapeutics.
  • We are also seeing clinical benefits with disease stabilizations in patients with relapsed/refractory metastatic or advanced solid tumors.
  • Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small molecule therapies that address emerging targets in oncology.
  • Ryvu Therapeutics has signed multiple partnering and licensing deals with global companies, including Merck, Menarini Group, Galapagos and Exelixis.

Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022

Retrieved on: 
Thursday, May 5, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Other Health, COVID-19, Cancer, U.S. Securities and Exchange Commission, CD38, Private Securities Litigation Reform Act, Tumor necrosis factor, Hematological Cancer Research Investment and Education Act, Multiple myeloma, B cell, Instagram, Twitter, Immortalised cell line, Chronic myelogenous leukemia, Cell, RPMI, Safety, CA, Poster, Phenotype, Patient, Immunotherapy, PST, Security (finance), ISCT, FDA, LAMP1, Risk, K562, Therapy, Facebook, Lymphatic system, LinkedIn, MM, SEC, Hematology, Technology, International Society, NAM, CISH, NK, Vaccine, Communications satellite, Pharmaceutical industry

GDA-301 is an investigational genetically modified NAM-NK cell therapy candidate aimed at targeting hematologic malignancies and solid tumors.

Key Points: 
  • GDA-301 is an investigational genetically modified NAM-NK cell therapy candidate aimed at targeting hematologic malignancies and solid tumors.
  • The potency and cytotoxicity data suggest that GDA-301 represents a novel potential immunotherapeutic targeting hematologic malignancies as well as solid tumors.
  • GDA-601 is an investigational genetically engineered NAM-NK cell therapy candidate designed to target multiple myeloma (MM) cells.
  • Gamida Cell is pioneering a diverse immunotherapy pipeline of potentially curative cell therapies for patients with solid tumor and blood cancers and other serious blood diseases.

Immunomic Therapeutics Reports Preclinical Data on Its MCPγV-LT and Her2/Neu DNA Vaccines at the American Association for Cancer Research (AACR) Annual Meeting 2022

Retrieved on: 
Friday, April 8, 2022
Science, Other Science, Biotechnology, Research, Oncology, General Health, Health, Clinical Trials, Therapy, Degenerative disease, Antigen presentation, UNITE, HER2, Vaccine, TAAS, Immunomics, Genome, Association, American Association for Cancer Research, Technology, APC, MCC, LAMP, CD8, MHC II, University, History, Trial of the century, Cancer, CD4, American Association, Immune system, MHC, CD40, CD154, Department, CD40L, ITI, Electroporation, DNA, LAMP1, Merkel cell polyomavirus, B cell, Survival, AACR, Poster, Doctor of Philosophy, Merkel-cell carcinoma, Allergy, Myelocyte, University of Washington, Patient, Company, Infection, Vaccination, Tumor microenvironment, Antigen, Neoplasm, Safety, Mouse, Pharmaceutical industry, MD, Medicine, Angela Merkel

The posters are accessible on the "Posters" section of Immunomic Therapeutics website at: https://www.immunomix.com/media/posters/ .

Key Points: 
  • The posters are accessible on the "Posters" section of Immunomic Therapeutics website at: https://www.immunomix.com/media/posters/ .
  • The majority of Merkel cell carcinomas (MCC), a rare and highly aggressive type of neuroendocrine skin cancer, are associated with Merkel cell polyomavirus (MCPyV) infection.
  • LTS220A, encoding a mutated form of MCPV-LT that diminishes its pro-oncogenic properties, was introduced into the UNITE platform.
  • We are highly encouraged by the data from the preclinical development for Her2-LAMP-sCD40L vaccine, stated Teri Heiland, PhD, Chief Scientific Officer of Immunomic Therapeutics.

Homology Medicines Announces Presentations on HMI-203 Investigational Gene Therapy for Hunter Syndrome and Broad Applicability of AAVHSC Platform for Lysosomal Storage Disorders at the 18th Annual WORLDSymposium™ Meeting

Retrieved on: 
Thursday, February 10, 2022
Hearing loss, Motion, Glycogen storage disease, Gene, Private Securities Litigation Reform Act, Phenylketonuria, Clinical trial, Adult, Therapy, Cross, MPS II, Maintenance, COVID-19, Caregiver, Health, SEC, I2S, Cell, ERT, Evidence, MLD, Antibody, Central nervous system, CNS, Hunter syndrome, Biomarker, JumpStart, Enzyme replacement therapy, Nasdaq, KOL, Safety, Gene editing, Pain, Lists of people executed in the United States, National, Disease, Glycosaminoglycan, Microdeletion syndrome, LAMP1, Paroxysmal nocturnal hemoglobinuria, GLOBE, Patient, IDS, Mark (given name), MPS, Tropism, PKU, PNH, Failure, II, Pharmaceutical industry, Phosphorus, Dentistry, Vaccine, IND, Hunting

BEDFORD, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today multiple presentations on HMI-203 gene therapy candidate for the treatment of Hunter syndrome (MPS II), which is being evaluated in juMPStart, a Phase 1 open-label, dose-escalation clinical trial in adults with Hunter syndrome. In oral platform presentations, key eligibility criteria and planned endpoints for the juMPStart trial were discussed and data from the HMI-203 IND-enabling studies were presented. Homology also shared patient, caregiver and key opinion leader (KOL) feedback on the unmet medical need in Hunter syndrome, despite the availability of enzyme replacement therapy (ERT), and the potential for a one-time gene therapy for patients that could impact peripheral and central nervous system (CNS) manifestations. These presentations at the 18th Annual WORLDSymposium™ Meeting also included data on Homology’s AAVHSC platform and potential to treat additional lysosomal storage disorders, including metachromatic leukodystrophy (MLD), based on CNS transduction in non-human primates (NHPs).

Key Points: 
  • These presentations at the 18th Annual WORLDSymposium Meeting also included data on Homologys AAVHSC platform and potential to treat additional lysosomal storage disorders, including metachromatic leukodystrophy (MLD), based on CNS transduction in non-human primates (NHPs).
  • These presentations highlight how Homologys gene therapy approach to Hunter syndrome and other lysosomal storage diseases is developed to target both the peripheral as well as the CNS manifestations of these multi-organ disorders, stated Albert Seymour, Ph.D., Chief Scientific Officer of Homology Medicines.
  • Lastly, in the poster titled, AAVHSCs and CNS-Targeting Gene Therapy for Lysosomal Storage Disorders, the potential of utilizing AAVHSCs for lysosomal storage disorders was presented.
  • Homologys clinical programs include HMI-102, an investigational gene therapy for adults with phenylketonuria (PKU); HMI-103, a gene editing candidate for PKU; and HMI-203, an investigational gene therapy for Hunter syndrome.